A phase 1 pooled PK/PD analysis of bone resorption biomarkers for odanacatib, a Cathepsin K inhibitor.
Adult
Aged
Biomarkers
/ urine
Biphenyl Compounds
/ administration & dosage
Bone Density Conservation Agents
/ administration & dosage
Bone Resorption
/ diagnosis
Cathepsin K
/ antagonists & inhibitors
Creatinine
/ urine
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Monitoring
/ methods
Female
Healthy Volunteers
Humans
Male
Middle Aged
Peptide Fragments
/ urine
Procollagen
/ urine
Treatment Outcome
Young Adult
Cathepsin K
Modeling
Odanacatib
PK/PD
Phase 1
Journal
Journal of pharmacokinetics and pharmacodynamics
ISSN: 1573-8744
Titre abrégé: J Pharmacokinet Pharmacodyn
Pays: United States
ID NLM: 101096520
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
24
02
2020
accepted:
26
06
2020
pubmed:
11
7
2020
medline:
21
9
2021
entrez:
11
7
2020
Statut:
ppublish
Résumé
To develop a framework for evaluating the resorption effects of Cathepsin K (CatK) inhibitors and to inform dose regimen selection, a pharmacokinetic/pharmacodynamic (PK/PD) model for odanacatib (ODN) was developed based upon data from Phase 1 studies. Pooled PK/PD data from 11 studies (N = 249) were fit reasonably to a population inhibitory sigmoid E
Identifiants
pubmed: 32647957
doi: 10.1007/s10928-020-09699-9
pii: 10.1007/s10928-020-09699-9
doi:
Substances chimiques
Biomarkers
0
Biphenyl Compounds
0
Bone Density Conservation Agents
0
Peptide Fragments
0
Procollagen
0
procollagen Type I N-terminal peptide
0
Creatinine
AYI8EX34EU
CTSK protein, human
EC 3.4.22.38
Cathepsin K
EC 3.4.22.38
odanacatib
N673F6W2VH
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM